CALIFORNIA LIFE SCIENCES

Support full funding across HHS departments

Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care

Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries

Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Oppose Most Favored Nation style drug pricing policies Support Investigation-al New Drug Pilot Program to accelerate clinical trial timelines Support bipartisan effort to address health care workforce shortage Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user

Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication

Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit

Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Oppose overly restrictive proposals that would provide coverage for breakthrough medical devices Support robust funding for the NIH in FY2027 appropriations

Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem

Support robust domestic supply chain development and manufacturing ecosystem

Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs

Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment

Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry